Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 33, Issue 4, Pages 599-613Publisher
ELSEVIER SCI LTD
DOI: 10.1006/jmcc.2000.1346
Keywords
sodium channel; antiarrhythmic drugs; lidocaine; flecainide; long QT syndrome; Brugada syndrome
Categories
Funding
- NIGMS NIH HHS [R01 GM56307] Funding Source: Medline
Ask authors/readers for more resources
Cardiac sodium (Na) channels are dynamic molecules that undergo rapid structural changes in response to the changing electrical field in the myocardium. Inherited mutations in SCN5A, the gene encoding the cardiac Na channel, provoke life-threatening cardiac arrhythmias, often by modifying these voltage-dependent conformational changes. These disorders (i.e., the long QT syndrome and Brugada syndrome) may serve as valuable models for understanding the mechanistic linkages between Na channel dysfunction and cardiac arrhythmias in more common, acquired conditions such as cardiac ischemia. In addition, the balance between therapeutic and adverse effects from Na channel blockade by antiarrhythmic compounds may be shifted by subtle alterations in Na channel function. This review examines recent studies that tie key loci in the Na channel primary sequence to its dynamic function, while examining the emerging themes linking Na channel structure, function, and pharmacology to inherited and acquired disorders of cardiac excitability. (C) 2001 Academic Press.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available